Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory

Cancer Immunology, Immunotherapy

Volumn 56, Issue 11, 2007, Pages 1765-1774

  Neal, Zane C ^a,b   Sondel, Paul M ^b,c   Bates, Mary Kay ^a   Gillies, Stephen D ^d   Herweijer, Hans ^a  

^a Mirus Bio Corporation   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d EMD SERONO INC   (United States)

Author keywords

Flt3 L; hu14.18 IL 2; Hydrodynamic gene delivery; Immunocytokine; Neuroblastoma

Indexed keywords

CYTOKINE ANTIBODY; FLT3 LIGAND; INTERLEUKIN 2 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE THERAPY; HYDRODYNAMICS BASED TRANSFECTION; LONG TERM MEMORY; MONOTHERAPY; MOUSE; NATURAL KILLER T CELL; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; GENE THERAPY; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; SPLEEN; TIME FACTORS; TUMOR ESCAPE;

EID: 34548190228     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0320-5     Document Type: Article

References (41)

1. Algarra I, Cabrera T, Garrido F (2000) The HLA crossroad in tumor immunology. Hum Immunol 61:65-73
2. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904-910
3. Bubenik J (2003) Tumour MHC class I downregulation and immunotherapy (review). Oncol Rep 10:2005-2008
4. Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, Sondel P (2004) Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 27:211-219
5. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148
6. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998
8. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD (2005) Interferon-gamma and cancer immunoediting. Immunol Res 32:231-245
9. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia ME (2003) Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 9:5228-5237
10. Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76-81
11. Greene LA, Shain W, Chalazonitis A, Breakfield X, Minna J, Coon HG, Nirenberg M (1975) Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. Proc Natl Acad Sci USA 72:4923-7
12. Gumperz JE, Parham P (1995) The enigma of the natural killer cell. Nature 378:245-248
13. Hagstrom JE, Hegge J, Zhang G, Noble M, Budker V, Lewis DL, Herweijer H, Wolff JA (2004) A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 10:386-398
14. He Y, Pimenov AA, Nayak JV, Plowey J, Falo LD Jr, Huang L (2000) Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther 11:547-554
15. Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM (2001) The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61:1500-1507
16. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB (2005) Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther 5:1303-1315
17. Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ (2002) Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3:83-90
18. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999-1005
19. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P (2004) Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22:4463-4473
20. Lanza F, Latorraca A, Moretti S, Castagnari B, Ferrari L, Castoldi G (1997) Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. Cytometry 30:134-144
21. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6:1258-1266
22. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA (1997) Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89:1586-1594
23. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706-1715
24. Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ (1994) Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 83:2795-2801
25. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184:1953-1962
26. Moretta A (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2:957-964
27. Munz C, Steinman RM, Fujii S (2005) Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 202:203-207
28. Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM (2004) NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother 53:41-52
29. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10:4839-4847
30. Neal ZC, Bates MK, Albertini MR and Herweijer H (2007) Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity. Mol Ther 15:422-430
31. Rees RC, Mian S (1999) Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother 48:374-381
32. Reisfeld RA (1992) Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Pigment Cell Res Suppl 2:109-112
33. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161:2817-2824
34. Silver DF, Hempling RE, Piver MS, Repasky EA (2000) Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 77:377-382
35. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861
36. van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ (2003) CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 63:5595-5600
37. Vonderheide RH (2002) Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21:674-679
38. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E (2005) Natural-killer cells and dendritic cells: "l'union fait la force". Blood 106:2252-2258
39. Wells DJ (2004) Opening the floodgates: clinically applicable hydrodynamic delivery of plasmid DNA to skeletal muscle. Mol Ther 10:207-208
40. Zhang G, Budker V, Wolff JA (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10:1735-1737
41. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627-3630